Pfizer says its drug is best hope vs. Alzheimer's
Quick ReadPfizer Inc research chief Mikael Dolsten said the company's experimental treatment for Alzheimer's disease is the drug industry's "best chance" to change the course of the memory-robbing illness.
Dolsten, speaking at the BIO CEO and investor conference in New York, would not predict whether the drug being developed with Johnson & Johnson would work.
"This is so far the best chance the industry has for disease modification in Alzheimer's," he said. Dolsten said Pfizer's drug, bapineuzumab, had far more complete and compelling data from already finished mid-stage clinical trials than...
